| Year |
Citation |
Score |
| 2012 |
Phan-Ba R, Belachew S, Outteryck O, Moonen G, Sindic C, Vokaer M, Vermersch P. The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas? Neurology. 79: 1067-9. PMID 22914844 DOI: 10.1212/Wnl.0B013E31826846B4 |
0.479 |
|
| 2012 |
Lommers E, Lecrompe L, Moonen G, Phan-Ba R, Belachew S. [Vitamin D tweets light to genes in multiple sclerosis]. Revue Mã©Dicale De Liã¨Ge. 67: 359-65. PMID 22891491 |
0.416 |
|
| 2012 |
Phan-Ba R, Calay P, Grodent P, Delrue G, Lommers E, Delvaux V, Moonen G, Nagels G, Belachew S. A corrected version of the Timed-25 Foot Walk Test with a dynamic start to capture the maximum ambulation speed in multiple sclerosis patients. Neurorehabilitation. 30: 261-6. PMID 22672939 DOI: 10.3233/Nre-2012-0754 |
0.489 |
|
| 2012 |
Phan-Ba R, Calay P, Grodent P, Delrue G, Lommers E, Delvaux V, Moonen G, Belachew S. Motor fatigue measurement by distance-induced slow down of walking speed in multiple sclerosis. Plos One. 7: e34744. PMID 22514661 DOI: 10.1371/Journal.Pone.0034744 |
0.476 |
|
| 2012 |
Phan-Ba R, Lommers E, Moonen G, Belachew S, Nath A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 78: 73; author response . PMID 22201114 DOI: 10.1212/01.Wnl.0000410335.08123.Dc |
0.494 |
|
| 2012 |
Phan-Ba R, Lommers E, Tshibanda L, Calay P, Dubois B, Moonen G, Clifford D, Belachew S. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. Journal of Neurology, Neurosurgery, and Psychiatry. 83: 224-6. PMID 22013244 DOI: 10.1136/Jnnp-2011-300511 |
0.486 |
|
| 2011 |
Phan-Ba R, Lambinet N, Louis E, Delvenne P, Tshibanda L, Boverie J, Moonen G, Belachew S. Natalizumab to kill two birds with one stone: a case of celiac disease and multiple sclerosis. Inflammatory Bowel Diseases. 17: E62-3. PMID 21472830 DOI: 10.1002/Ibd.21716 |
0.476 |
|
| 2011 |
Phan-Ba R, Pace A, Calay P, Grodent P, Douchamps F, Hyde R, Hotermans C, Delvaux V, Hansen I, Moonen G, Belachew S. Comparison of the timed 25-foot and the 100-meter walk as performance measures in multiple sclerosis. Neurorehabilitation and Neural Repair. 25: 672-9. PMID 21436388 DOI: 10.1177/1545968310397204 |
0.483 |
|
| 2011 |
Phan-Ba R, Bisig B, Deprez M, De Prijck B, Delrue G, Herens C, Moonen G, Belachew S, de Leval L. Primary central nervous system lymphoma in a patient treated with natalizumab. Annals of Neurology. 69: 1060-1; author reply. PMID 21328606 DOI: 10.1002/ana.22296 |
0.426 |
|
| 2011 |
Beukelaers P, Vandenbosch R, Caron N, Nguyen L, Belachew S, Moonen G, Kiyokawa H, Barbacid M, Santamaria D, Malgrange B. Cdk6-dependent regulation of G(1) length controls adult neurogenesis. Stem Cells (Dayton, Ohio). 29: 713-24. PMID 21319271 DOI: 10.1002/Stem.616 |
0.792 |
|
| 2011 |
Belachew S, Phan-Ba R, Bartholomé E, Delvaux V, Hansen I, Calay P, Hafsi KE, Moonen G, Tshibanda L, Vokaer M. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 18: 240-5. PMID 20561044 DOI: 10.1111/J.1468-1331.2010.03112.X |
0.509 |
|
| 2010 |
Schoemans R, Aigrot MS, Wu C, Marée R, Hong P, Belachew S, Josse C, Lubetzki C, Bours V. Oligodendrocyte development and myelinogenesis are not impaired by high concentrations of phenylalanine or its metabolites. Journal of Inherited Metabolic Disease. 33: 113-20. PMID 20151197 DOI: 10.1007/S10545-010-9052-3 |
0.328 |
|
| 2009 |
Hotermans C, Belachew S, Moonen G, Delwaide J. Severe liver dysfunction in a patient with multiple sclerosis: the guilty party is not always the disease-modifying therapy. Multiple Sclerosis (Houndmills, Basingstoke, England). 15: 1378-9. PMID 19965562 DOI: 10.1177/1352458509345910 |
0.475 |
|
| 2009 |
Jedidi Z, Jedidi H, Moonen G, Belachew S. [Monoclonal antibodies in neurology]. Revue Mã©Dicale De Liã¨Ge. 64: 305-9. PMID 19642464 |
0.415 |
|
| 2009 |
Borgs L, Beukelaers P, Vandenbosch R, Nguyen L, Moonen G, Maquet P, Albrecht U, Belachew S, Malgrange B. Period 2 regulates neural stem/progenitor cell proliferation in the adult hippocampus. Bmc Neuroscience. 10: 30. PMID 19327139 DOI: 10.1186/1471-2202-10-30 |
0.812 |
|
| 2009 |
Borgs L, Beukelaers P, Vandenbosch R, Belachew S, Nguyen L, Malgrange B. Cell "circadian" cycle: new role for mammalian core clock genes. Cell Cycle (Georgetown, Tex.). 8: 832-7. PMID 19221497 DOI: 10.4161/Cc.8.6.7869 |
0.743 |
|
| 2009 |
Vandenbosch R, Borgs L, Beukelaers P, Belachew S, Moonen G, Nguyen L, Malgrange B. Adult neurogenesis and the diseased brain. Current Medicinal Chemistry. 16: 652-66. PMID 19199929 DOI: 10.2174/092986709787458371 |
0.795 |
|
| 2009 |
Creppe C, Malinouskaya L, Volvert ML, Gillard M, Close P, Malaise O, Laguesse S, Cornez I, Rahmouni S, Ormenese S, Belachew S, Malgrange B, Chapelle JP, Siebenlist U, Moonen G, et al. Elongator controls the migration and differentiation of cortical neurons through acetylation of alpha-tubulin. Cell. 136: 551-64. PMID 19185337 DOI: 10.1016/J.Cell.2008.11.043 |
0.732 |
|
| 2008 |
Breuskin I, Bodson M, Thelen N, Thiry M, Nguyen L, Belachew S, Lefebvre PP, Malgrange B. Strategies to regenerate hair cells: identification of progenitors and critical genes. Hearing Research. 236: 1-10. PMID 17920797 DOI: 10.1016/J.Heares.2007.08.007 |
0.722 |
|
| 2007 |
Jablonska B, Aguirre A, Vandenbosch R, Belachew S, Berthet C, Kaldis P, Gallo V. Cdk2 is critical for proliferation and self-renewal of neural progenitor cells in the adult subventricular zone. The Journal of Cell Biology. 179: 1231-45. PMID 18086919 DOI: 10.1083/Jcb.200702031 |
0.783 |
|
| 2007 |
Vandenbosch R, Borgs L, Beukelaers P, Foidart A, Nguyen L, Moonen G, Berthet C, Kaldis P, Gallo V, Belachew S, Malgrange B. CDK2 is dispensable for adult hippocampal neurogenesis. Cell Cycle (Georgetown, Tex.). 6: 3065-9. PMID 18073538 DOI: 10.4161/Cc.6.24.5048 |
0.803 |
|
| 2007 |
Belachew S, Magis D, Lievens I, Cuvelier ML, Rikir E, Garraux G, Hotermans C, Salmon E, Sadzot B, Cambron L, Maquet P, Poirrier R, Moonen G. [Therapeutic armamentarium in neurology: the birth of a new era]. Revue Mã©Dicale De Liã¨Ge. 62: 432-48. PMID 17725219 |
0.428 |
|
| 2006 |
Sohn J, Natale J, Chew LJ, Belachew S, Cheng Y, Aguirre A, Lytle J, Nait-Oumesmar B, Kerninon C, Kanai-Azuma M, Kanai Y, Gallo V. Identification of Sox17 as a transcription factor that regulates oligodendrocyte development. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 9722-35. PMID 16988043 DOI: 10.1523/Jneurosci.1716-06.2006 |
0.587 |
|
| 2006 |
Nguyen L, Borgs L, Vandenbosch R, Mangin JM, Beukelaers P, Moonen G, Gallo V, Malgrange B, Belachew S. The Yin and Yang of cell cycle progression and differentiation in the oligodendroglial lineage. Mental Retardation and Developmental Disabilities Research Reviews. 12: 85-96. PMID 16807909 DOI: 10.1002/Mrdd.20103 |
0.784 |
|
| 2005 |
Mangin JM, Nguyen L, Gougnard C, Hans G, Rogister B, Belachew S, Moonen G, Legendre P, Rigo JM. Developmental regulation of beta-carboline-induced inhibition of glycine-evoked responses depends on glycine receptor beta subunit expression. Molecular Pharmacology. 67: 1783-96. PMID 15722459 DOI: 10.1124/Mol.104.007435 |
0.681 |
|
| 2005 |
Hans G, Wislet-Gendebien S, Lallemend F, Robe P, Rogister B, Belachew S, Nguyen L, Malgrange B, Moonen G, Rigo JM. Peripheral benzodiazepine receptor (PBR) ligand cytotoxicity unrelated to PBR expression. Biochemical Pharmacology. 69: 819-30. PMID 15710359 DOI: 10.1016/J.Bcp.2004.11.029 |
0.747 |
|
| 2005 |
Hans G, Malgrange B, Lallemend F, Crommen J, Wislet-Gendebien S, Belachew S, Robe P, Rogister B, Moonen G, Rigo JM. Beta-carbolines induce apoptosis in cultured cerebellar granule neurons via the mitochondrial pathway. Neuropharmacology. 48: 105-17. PMID 15617732 DOI: 10.1016/J.Neuropharm.2004.09.001 |
0.674 |
|
| 2004 |
Belachew S, Gallo V. Synaptic and extrasynaptic neurotransmitter receptors in glial precursors' quest for identity. Glia. 48: 185-96. PMID 15390115 DOI: 10.1002/Glia.20077 |
0.59 |
|
| 2004 |
Vautier F, Belachew S, Chittajallu R, Gallo V. Shaker-type potassium channel subunits differentially control oligodendrocyte progenitor proliferation. Glia. 48: 337-45. PMID 15390108 DOI: 10.1002/Glia.20088 |
0.761 |
|
| 2004 |
Aguirre AA, Chittajallu R, Belachew S, Gallo V. NG2-expressing cells in the subventricular zone are type C-like cells and contribute to interneuron generation in the postnatal hippocampus. The Journal of Cell Biology. 165: 575-89. PMID 15159421 DOI: 10.1083/Jcb.200311141 |
0.774 |
|
| 2004 |
Nguyen L, Malgrange B, Breuskin I, Lallemend F, Hans G, Moonen G, Belachew S, Rigo JM. Striatal PSA-NCAM(+) precursor cells from the newborn rat express functional glycine receptors. Neuroreport. 15: 583-7. PMID 15094457 DOI: 10.1097/00001756-200403220-00003 |
0.759 |
|
| 2003 |
Malgrange B, Knockaert M, Belachew S, Nguyen L, Moonen G, Meijer L, Lefebvre PP. The inhibition of cyclin-dependent kinases induces differentiation of supernumerary hair cells and Deiters' cells in the developing organ of Corti. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 17: 2136-8. PMID 12958157 DOI: 10.1096/Fj.03-0035Fje |
0.765 |
|
| 2003 |
Nguyen L, Malgrange B, Rocher V, Hans G, Moonen G, Rigo JM, Belachew S. Chemical inhibitors of cyclin-dependent kinases control proliferation, apoptosis and differentiation of oligodendroglial cells. International Journal of Developmental Neuroscience : the Official Journal of the International Society For Developmental Neuroscience. 21: 321-6. PMID 12927580 DOI: 10.1016/S0736-5748(03)00075-3 |
0.758 |
|
| 2003 |
Nguyen L, Rigo JM, Malgrange B, Moonen G, Belachew S. Untangling the functional potential of PSA-NCAM-expressing cells in CNS development and brain repair strategies. Current Medicinal Chemistry. 10: 2185-96. PMID 12871092 DOI: 10.2174/0929867033456774 |
0.796 |
|
| 2003 |
Nguyen L, Malgrange B, Breuskin I, Bettendorff L, Moonen G, Belachew S, Rigo JM. Autocrine/paracrine activation of the GABA(A) receptor inhibits the proliferation of neurogenic polysialylated neural cell adhesion molecule-positive (PSA-NCAM+) precursor cells from postnatal striatum. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 3278-94. PMID 12716935 DOI: 10.1523/Jneurosci.23-08-03278.2003 |
0.764 |
|
| 2003 |
Belachew S, Chittajallu R, Aguirre AA, Yuan X, Kirby M, Anderson S, Gallo V. Postnatal NG2 proteoglycan-expressing progenitor cells are intrinsically multipotent and generate functional neurons. The Journal of Cell Biology. 161: 169-86. PMID 12682089 DOI: 10.1083/Jcb.200210110 |
0.78 |
|
| 2002 |
Yuan X, Chittajallu R, Belachew S, Anderson S, McBain CJ, Gallo V. Expression of the green fluorescent protein in the oligodendrocyte lineage: a transgenic mouse for developmental and physiological studies. Journal of Neuroscience Research. 70: 529-45. PMID 12404507 DOI: 10.1002/Jnr.10368 |
0.757 |
|
| 2002 |
Belachew S, Aguirre AA, Wang H, Vautier F, Yuan X, Anderson S, Kirby M, Gallo V. Cyclin-dependent kinase-2 controls oligodendrocyte progenitor cell cycle progression and is downregulated in adult oligodendrocyte progenitors. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 8553-62. PMID 12351729 DOI: 10.1523/Jneurosci.22-19-08553.2002 |
0.6 |
|
| 2002 |
Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, Leprince P, Moonen G, Selak I, Matagne A, Klitgaard H. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. British Journal of Pharmacology. 136: 659-72. PMID 12086975 DOI: 10.1038/Sj.Bjp.0704766 |
0.731 |
|
| 2002 |
Nguyen L, Malgrange B, Belachew S, Rogister B, Rocher V, Moonen G, Rigo JM. Functional glycine receptors are expressed by postnatal nestin-positive neural stem/progenitor cells. The European Journal of Neuroscience. 15: 1299-305. PMID 11994124 DOI: 10.1046/J.1460-9568.2002.01966.X |
0.783 |
|
| 2002 |
Malgrange B, Belachew S, Thiry M, Nguyen L, Rogister B, Alvarez ML, Rigo JM, Van De Water TR, Moonen G, Lefebvre PP. Proliferative generation of mammalian auditory hair cells in culture. Mechanisms of Development. 112: 79-88. PMID 11850180 DOI: 10.1016/S0925-4773(01)00642-6 |
0.764 |
|
| 2001 |
Belachew S, Yuan X, Gallo V. Unraveling oligodendrocyte origin and function by cell-specific transgenesis. Developmental Neuroscience. 23: 287-98. PMID 11756744 DOI: 10.1159/000048712 |
0.578 |
|
| 2001 |
Nguyen L, Rigo JM, Rocher V, Belachew S, Malgrange B, Rogister B, Leprince P, Moonen G. Neurotransmitters as early signals for central nervous system development. Cell and Tissue Research. 305: 187-202. PMID 11545256 DOI: 10.1007/S004410000343 |
0.782 |
|
| 2001 |
Fumal A, Belachew S, Moonen G, David JL. [Clinical case of the month. Report of a case of antiphospholipid syndrome]. Revue Mã©Dicale De Liã¨Ge. 56: 480-3. PMID 11523297 |
0.392 |
|
| 2000 |
Belachew S, Malgrange B, Rigo JM, Rogister B, Leprince P, Hans G, Nguyen L, Moonen G. Glycine triggers an intracellular calcium influx in oligodendrocyte progenitor cells which is mediated by the activation of both the ionotropic glycine receptor and Na+-dependent transporters. The European Journal of Neuroscience. 12: 1924-30. PMID 10886333 DOI: 10.1046/J.1460-9568.2000.00085.X |
0.731 |
|
| 1999 |
Chanas-Sacré G, Mazy-Servais C, Wattiez R, Pirard S, Rogister B, Patton JG, Belachew S, Malgrange B, Moonen G, Leprince P. Identification of PSF, the polypyrimidine tract-binding protein-associated splicing factor, as a developmentally regulated neuronal protein. Journal of Neuroscience Research. 57: 62-73. PMID 10397636 DOI: 10.1002/(Sici)1097-4547(19990701)57:1<62::Aid-Jnr7>3.0.Co;2-Y |
0.706 |
|
| 1999 |
Rogister B, Belachew S, Moonen G. Oligodendrocytes: from development to demyelinated lesion repair. Acta Neurologica Belgica. 99: 32-9. PMID 10218090 |
0.527 |
|
| 1999 |
Belachew S, Rogister B, Rigo JM, Malgrange B, Moonen G. Neurotransmitter-mediated regulation of CNS myelination: a review. Acta Neurologica Belgica. 99: 21-31. PMID 10218089 |
0.678 |
|
| 1998 |
Belachew S, Rogister B, Rigo JM, Malgrange B, Mazy-Servais C, Xhauflaire G, Coucke P, Moonen G. Cultured oligodendrocyte progenitors derived from cerebral cortex express a glycine receptor which is pharmacologically distinct from the neuronal isoform. The European Journal of Neuroscience. 10: 3556-64. PMID 9824468 DOI: 10.1046/J.1460-9568.1998.00369.X |
0.697 |
|
| 1998 |
Belachew S, Malgrange B, Rigo JM, Rogister B, Coucke P, Mazy-Servais C, Moonen G. Developmental regulation of neuroligand-induced responses in cultured oligodendroglia. Neuroreport. 9: 973-80. PMID 9601652 DOI: 10.1097/00001756-199804200-00004 |
0.685 |
|
| 1997 |
Malgrange B, Rigo JM, Lefebvre PP, Coucke P, Goffin F, Xhauflaire G, Belachew S, Van de Water TR, Moonen G. Diazepam-insensitive GABAA receptors on postnatal spiral ganglion neurones in culture. Neuroreport. 8: 591-6. PMID 9106729 DOI: 10.1097/00001756-199702100-00003 |
0.692 |
|
| 1996 |
Malgrange B, Rigo JM, Coucke P, Belachew S, Rogister B, Moonen G. Beta-carbolines induce apoptotic death of cerebellar granule neurones in culture. Neuroreport. 7: 3041-5. PMID 9116236 DOI: 10.1097/00001756-199611250-00049 |
0.679 |
|
| 1996 |
Rigo JM, Belachew S, Coucke P, Leprince P, Malgrange B, Rogister B, Moonen G. Astroglia-released factor with negative allosteric modulatory properties at the GABA A receptor. Biochemical Pharmacology. 52: 465-73. PMID 8687501 DOI: 10.1016/0006-2952(96)00249-3 |
0.672 |
|
| 1996 |
Belachew S, Malgrange B, Rigo J, Register B, Moonen G. 129 Developmental regulation of neurotransmitters- and neuropeptides-induced responses in oligodendroglial cells cultured IN VITRO International Journal of Developmental Neuroscience. 14: 81-81. DOI: 10.1016/0736-5748(96)80319-4 |
0.692 |
|
| 1996 |
Malgrange B, Rigo JM, Coucke P, Belachew S, Rogister B, Moonen G. Can a negative allosteric modulation of GABA(A) receptor kill neurons? Neuroreport. 7: R1. |
0.54 |
|
| 1994 |
Rigo JM, Belachew S, Lefebvre PP, Leprince P, Malgrange B, Rogister B, Kettenmann H, Moonen G. Astroglia-released factor shows similar effects as benzodiazepine inverse agonists. Journal of Neuroscience Research. 39: 364-76. PMID 7884817 DOI: 10.1002/Jnr.490390403 |
0.706 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2016 |
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, ... ... Belachew S, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. The New England Journal of Medicine. PMID 28002688 DOI: 10.1056/Nejmoa1606468 |
0.288 |
|
| 2017 |
Giovannoni G, Cutter G, Pia-Sormani M, Belachew S, Hyde R, Koendgen H, Knappertz V, Tomic D, Leppert D, Herndon R, Wheeler-Kingshott CA, Ciccarelli O, Selwood D, di Cantogno EV, Ben-Amor AF, et al. Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Multiple Sclerosis and Related Disorders. 12: 70-78. PMID 28283111 DOI: 10.1016/J.Msard.2017.01.007 |
0.278 |
|
| 2020 |
Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, Model F, Koendgen H, Manfrini M, Belachew S, Hauser SL. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. Jama Neurology. PMID 32511687 DOI: 10.1001/Jamaneurol.2020.1568 |
0.273 |
|
| 2018 |
Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Lublin F, Wang Q, Model F, Wei W, Garren H, Manfrini M, Belachew S, Hauser S. 061 Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE) Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Anzan.60 |
0.271 |
|
| 2018 |
Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C, Deol-Bhullar G, Garren H, Chin P, Belachew S, Kappos L. Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology. PMID 30155979 DOI: 10.1002/Ana.25313 |
0.271 |
|
| 2019 |
Barkhof F, Kappos L, Wolinsky JS, Li DKB, Bar-Or A, Hartung HP, Belachew S, Han J, Julian L, Sauter A, Napieralski J, Koendgen H, Hauser SL. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology. PMID 31484710 DOI: 10.1212/Wnl.0000000000008189 |
0.265 |
|
| 2020 |
Elliott C, Arnold DL, Chen H, Ke C, Zhu L, Chang I, Cahir-McFarland E, Fisher E, Zhu B, Gheuens S, Scaramozza M, Beynon V, Franchimont N, Bradley DP, Belachew S. Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions. Ajnr. American Journal of Neuroradiology. PMID 32819894 DOI: 10.3174/Ajnr.A6742 |
0.265 |
|
| 2015 |
Voloshyna N, Havrdová E, Hutchinson M, Nehrych T, You X, Belachew S, Hotermans C, Paes D. Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 22: 570-7. PMID 25511792 DOI: 10.1111/Ene.12618 |
0.265 |
|
| 2017 |
Kappos L, Butzkueven H, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S, Trojano M. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458517709619. PMID 28554238 DOI: 10.1177/1352458517709619 |
0.263 |
|
| 2018 |
Jhuti G, Freitas R, Bennett I, Butzkueven H, Izquierdo G, Eichau S, Havrdova E, Horakova D, Duquette P, Prat A, Girard M, Grand'Maison F, Hupperts R, Lugaresi A, Onofrj M, ... ... Belachew S, et al. PND18 - PROGRESSION OF DISABILITY IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS: A RETROSPECTIVE COHORT STUDY USING DATA FROM THE MSBASE REGISTRY AND A CONTEXTUALISATION WITH AN EXISTING NATURAL HISTORY DATASET Value in Health. 21: S332. DOI: 10.1016/J.Jval.2018.09.1985 |
0.262 |
|
| 2018 |
Arnold DL, Kappos L, Hauser SL, Montalban X, Traboulsee A, Wolinsky JS, Manfrini M, Levesque V, Villoslada P, Belachew S, Model F, Hubeaux S, Bar-Or A. Long-term Reduction in Brain MRI Disease Activity and Atrophy after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis Multiple Sclerosis and Related Disorders. 26: 265. DOI: 10.1016/J.Msard.2018.10.104 |
0.262 |
|
| 2018 |
Fox EJ, Markowitz C, Applebee A, Montalban X, Wolinsky JS, Belachew S, Fiore D, Pei J, Musch B, Giovannoni G. Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458518808189. PMID 30415593 DOI: 10.1177/1352458518808189 |
0.261 |
|
| 2016 |
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, ... ... Belachew S, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. The New England Journal of Medicine. PMID 28002679 DOI: 10.1056/Nejmoa1601277 |
0.258 |
|
| 2013 |
Subramanyam M, Belachew S, Compton T. More on JC viremia in natalizumab-treated patients with multiple sclerosis. The New England Journal of Medicine. 369: 1279-80. PMID 24066762 DOI: 10.1056/Nejmc1308784#Sa1 |
0.257 |
|
| 2017 |
Giovannoni G, Arnold DL, Bar-Or A, Havrdová E, Kappos L, Lublin F, Traboulsee A, Belachew S, Han J, Hauser SL. PO129 Neda analysis by epoch in the opera studies of ocrelizumab Journal of Neurology, Neurosurgery, and Psychiatry. 88. DOI: 10.1136/Jnnp-2017-Abn.159 |
0.255 |
|
| 2020 |
Penner IK, McDougall F, Brown TM, Slota C, Doward L, Julian L, Belachew S, Miller D. Exploring the Impact of Fatigue in Progressive Multiple Sclerosis: A Mixed-Methods Analysis. Multiple Sclerosis and Related Disorders. 43: 102207. PMID 32505026 DOI: 10.1016/J.Msard.2020.102207 |
0.255 |
|
| 2020 |
Hauser SL, Kappos L, Arnold DL, Bar-Or A, Brochet B, Naismith RT, Traboulsee A, Wolinsky JS, Belachew S, Koendgen H, Levesque V, Manfrini M, Model F, Hubeaux S, Mehta L, et al. Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology. PMID 32690791 DOI: 10.1212/Wnl.0000000000010376 |
0.25 |
|
| 2012 |
Butzkueven H, Belachew S, Kappos L, Pellegrini F, Trojano M, Wiendl H, Zhang A, Hotermans C. Assessment of Baseline Characteristics, Treatment Efficacy, and Serious Adverse Events among Natalizumab-Treated MS Patients without Prior Treatment (P06.172) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P06.172 |
0.249 |
|
| 2019 |
Midaglia L, Mulero P, Montalban X, Graves J, Hauser SL, Julian L, Baker M, Schadrack J, Gossens C, Scotland A, Lipsmeier F, van Beek J, Bernasconi C, Belachew S, Lindemann M. Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study. Journal of Medical Internet Research. 21: e14863. PMID 31471961 DOI: 10.2196/14863 |
0.249 |
|
| 2010 |
Brouns R, Thijs V, Eyskens F, Van den Broeck M, Belachew S, Van Broeckhoven C, Redondo P, Hemelsoet D, Fumal A, Jeangette S, Verslegers W, Baker R, Hughes D, De Deyn PP. Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke; a Journal of Cerebral Circulation. 41: 863-8. PMID 20360539 DOI: 10.1161/Strokeaha.110.579409 |
0.248 |
|
| 2014 |
Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, Zhang A, Hotermans C, Belachew S. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. Journal of Neurology, Neurosurgery, and Psychiatry. 85: 1190-7. PMID 24532785 DOI: 10.1136/Jnnp-2013-306936 |
0.247 |
|
| 2018 |
Elliott C, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, Bernasconi C, Wei W, Belachew S, Arnold DL. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458518814117. PMID 30566027 DOI: 10.1177/1352458518814117 |
0.244 |
|
| 2011 |
Kappos L, Butzkueven H, Belachew S, Pellegrini F, Trojano M, Wiendl H, Zhang A, Paes D, Hotermans C. Relationship between baseline treatment history and post baseline relapses and serious adverse events in natalizumab-treated patients with multiple sclerosis F1000research. 2. DOI: 10.7490/F1000Research.1782.1 |
0.243 |
|
| 2019 |
Elliott C, Belachew S, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, Bernasconi C, Fecker J, Model F, Wei W, Arnold DL. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain : a Journal of Neurology. 142: 2787-2799. PMID 31497864 DOI: 10.1093/Brain/Awz212 |
0.243 |
|
| 2017 |
Giovannoni G, Arnold DL, Bar-Or A, Seze Jd, Hemmer B, Montalban X, Belachew S, Bernasconi C, Garren H, Wolinsky J. PO127 Composite confirmed disability progression in oratorio Journal of Neurology, Neurosurgery, and Psychiatry. 88. DOI: 10.1136/Jnnp-2017-Abn.157 |
0.242 |
|
| 2018 |
Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. Multiple Sclerosis and Related Disorders. 24: 11-19. PMID 29860197 DOI: 10.1016/J.Msard.2018.04.020 |
0.242 |
|
| 2018 |
Belachew S. Advancing the understanding of progression in multiple sclerosis: an interview with Shibeshih Belachew. Neurodegenerative Disease Management. PMID 29301440 DOI: 10.2217/Nmt-2017-0054 |
0.241 |
|
| 2016 |
Montalban X, Arnold DL, Bar-Or A, Séze JD, Giovannoni G, Hammer B, Rammohan K, Masterman D, Barnasconi C, Wei W, Belachew S, Chin P, Wolinski J, Stenager E. Evaluation of no evidence of progression using composite outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial Multiple Sclerosis Journal. 22. DOI: 10.1177/1352458516663068 |
0.24 |
|
| 2014 |
Lublin FD, Cutter G, Giovannoni G, Pace A, Campbell NR, Belachew S. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. Multiple Sclerosis and Related Disorders. 3: 705-11. PMID 25891549 DOI: 10.1016/J.Msard.2014.08.005 |
0.234 |
|
| 2020 |
Creagh A, Simillion C, Scotland A, Lipsmeier F, Bernasconi C, Belachew S, van Beek J, Baker M, Gossens C, Lindemann M, De Vos M. Smartphone-based remote assessment of upper extremity function for multiple sclerosis using the FLOODLIGHT draw a shape test. Physiological Measurement. PMID 32259798 DOI: 10.1088/1361-6579/Ab8771 |
0.233 |
|
| 2012 |
Butzkueven H, Belachew S, Kappos L, Pellegrini F, Trojano M, Wiendl H, Zhang A, Arnold R. Baseline characteristics, treatment efficacy, and serious adverse events in natalizumab-treated MS patients without prior treatment F1000research. 3. DOI: 10.7490/F1000Research.1090920.1 |
0.231 |
|
| 2012 |
Kappos L, Belachew S, Butzkueven H, Pellegrini F, Trojano M, Wiendl H, Zhang A, Hotermans C. Long-Term Safety and Efficacy and Association between Baseline Treatment History and Postbaseline Relapses in Multiple Sclerosis Patients Treated with Natalizumab in the TYSABRI(R) Observational Program (TOP) (P04.134) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P04.134 |
0.23 |
|
| 2021 |
Bame E, Tang H, Burns JC, Arefayene M, Michelsen K, Ma B, Marx I, Prince R, Roach AM, Poreci U, Donaldson D, Cullen P, Casey F, Zhu J, Carlile TM, ... ... Belachew S, et al. Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells. Clinical & Translational Immunology. 10: e1295. PMID 34141433 DOI: 10.1002/cti2.1295 |
0.226 |
|
| 2016 |
Wiendl H, Butzkueven H, Kappos L, Trojano M, Pellegrini F, Paes D, Zhang A, Belachew S. Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP). Plos One. 11: e0144834. PMID 26771747 DOI: 10.1371/Journal.Pone.0144834 |
0.225 |
|
| 2013 |
De Brabander I, Yperzeele L, Ceuterick-De Groote C, Brouns R, Baker R, Belachew S, Delbecq J, De Keulenaer G, Dethy S, Eyskens F, Fumal A, Hemelsoet D, Hughes D, Jeangette S, Nuytten D, et al. Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young. Clinical Neurology and Neurosurgery. 115: 1088-93. PMID 23219219 DOI: 10.1016/J.Clineuro.2012.11.003 |
0.224 |
|
| 2015 |
Spelman T, Kalincik T, Zhang A, Pellegrini F, Wiendl H, Kappos L, Tsvetkova L, Belachew S, Hyde R, Verheul F, Grand-Maison F, Izquierdo G, Grammond P, Duquette P, Lugaresi A, et al. Comparative efficacy of switching to natalizumab in active multiple sclerosis. Annals of Clinical and Translational Neurology. 2: 373-87. PMID 25909083 DOI: 10.1002/Acn3.180 |
0.219 |
|
| 2014 |
Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Annals of Neurology. 76: 802-12. PMID 25273271 DOI: 10.1002/Ana.24286 |
0.215 |
|
| 2008 |
Scholsem M, Scholtes F, Belachew S, Martin D. Acquired tonsillar herniation and syringomyelia after pleural effusion aspiration: case report. Neurosurgery. 62: E1172-3; discussion . PMID 18580789 DOI: 10.1227/01.Neu.0000325884.05871.Aa |
0.211 |
|
| 2017 |
Vermesch P, Giovannoni G, Havrdová E, Kappos L, Belachew S, Han J, Hauser SL. Analyse de l’absence d’activité clinique et IRM (NEDA) par périodes chez les patients atteints de SEP-R traités par ocrelizumab. Résultats des études de phase III : OPERA I et OPERA II Revue Neurologique. 173. DOI: 10.1016/J.Neurol.2017.01.201 |
0.182 |
|
| 2017 |
Vermesch P, Seze JD, Bernasconi C, Wei W, Belachew S, Chin P, Montalban X. Évaluation de l’absence de progression (NEP) en utilisant une mesure composite du handicap, chez les patients atteints de primaire progressive (SEP-PP) traités par ocrelizumab Revue Neurologique. 173. DOI: 10.1016/J.Neurol.2017.01.203 |
0.181 |
|
| 2008 |
Pitchot W, Polis M, Belachew S, Ansseau M. [Depression and neuroplasticity]. Revue Mã©Dicale De Liã¨Ge. 63: 372-7. PMID 18669207 |
0.149 |
|
| 2017 |
Montalban X, Belachew S, Wolinsky JS. Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis. The New England Journal of Medicine. 376: 1694. PMID 28445663 DOI: 10.1056/NEJMc1702076#SA5 |
0.128 |
|
| 2017 |
Hauser SL, Belachew Sh, Kappos L. Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis. The New England Journal of Medicine. 376: 1694. PMID 28445661 DOI: 10.1056/NEJMc1702076 |
0.128 |
|
| 2018 |
Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, et al. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 4: 2055217318760642. PMID 29568544 DOI: 10.1177/2055217318760642 |
0.126 |
|
| 2021 |
Elliott C, Momayyezsiahkal P, Arnold DL, Liu D, Ke J, Zhu L, Zhu B, George IC, Bradley DP, Fisher E, Cahir-McFarland E, Stys PK, Geurts JJG, Franchimont N, Gafson A, ... Belachew S, et al. Abnormalities in normal-appearing white matter from which multiple sclerosis lesions arise. Brain Communications. 3: fcab176. PMID 34557664 DOI: 10.1093/braincomms/fcab176 |
0.123 |
|
| 2023 |
Jiang X, Shen C, Caba B, Arnold DL, Elliott C, Zhu B, Fisher E, Belachew S, Gafson AR. Assessing the utility of magnetic resonance imaging-based "SuStaIn" disease subtyping for precision medicine in relapsing-remitting and secondary progressive multiple sclerosis. Multiple Sclerosis and Related Disorders. 77: 104869. PMID 37459715 DOI: 10.1016/j.msard.2023.104869 |
0.121 |
|
| 2022 |
Bühler A, Wolbers M, Model F, Wang Q, Belachew S, Manfrini M, Lorscheider J, Kappos L, Beyersmann J. Recurrent disability progression endpoints in multiple sclerosis clinical trials. Multiple Sclerosis (Houndmills, Basingstoke, England). 13524585221125382. PMID 36177953 DOI: 10.1177/13524585221125382 |
0.116 |
|
| 2022 |
Beynon V, George IC, Elliott C, Arnold DL, Ke J, Chen H, Zhu L, Ke C, Giovannoni G, Scaramozza M, Campbell N, Bradley DP, Franchimont N, Gafson A, Belachew S. Chronic lesion activity and disability progression in secondary progressive multiple sclerosis. Bmj Neurology Open. 4: e000240. PMID 35720980 DOI: 10.1136/bmjno-2021-000240 |
0.11 |
|
| 2023 |
Jiang X, Shen C, Teunissen CE, Wessels M, Zetterberg H, Giovannoni G, Singh CM, Caba B, Elliott C, Fisher E, de Moor C, Belachew S, Gafson AR. Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation. Multiple Sclerosis (Houndmills, Basingstoke, England). 13524585231176732. PMID 37317870 DOI: 10.1177/13524585231176732 |
0.104 |
|
| 2021 |
Arnold DL, Belachew S, Gafson AR, Gaetano L, Bernasconi C, Elliott C. Slowly expanding lesions are a marker of progressive MS - No. Multiple Sclerosis (Houndmills, Basingstoke, England). 13524585211017020. PMID 34474615 DOI: 10.1177/13524585211017020 |
0.099 |
|
| 2022 |
Caba B, Cafaro A, Lombard A, Arnold DL, Elliott C, Liu D, Jiang X, Gafson A, Fisher E, Belachew SM, Paragios N. Single-timepoint low-dimensional characterization and classification of acute versus chronic multiple sclerosis lesions using machine learning. Neuroimage. 265: 119787. PMID 36473647 DOI: 10.1016/j.neuroimage.2022.119787 |
0.095 |
|
| 2022 |
Chang I, Kappos L, Giovannoni G, Calabresi PA, Sandrock A, Cheng W, Xiao S, Riester K, Belachew S, Deykin A, Zhu B. Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 13524585221114997. PMID 36131595 DOI: 10.1177/13524585221114997 |
0.092 |
|
| 2008 |
Cuvelier ML, Léonard P, Rikir E, Belachew S. [HIV-related infections of the brain]. Revue Mã©Dicale De Liã¨Ge. 63: 342-8. PMID 18669202 |
0.091 |
|
| 2020 |
Cheng WY, Bourke AK, Lipsmeier F, Bernasconi C, Belachew S, Gossens C, Graves JS, Montalban X, Lindemann M. U-turn speed is a valid and reliable smartphone-based measure of multiple sclerosis-related gait and balance impairment. Gait & Posture. 84: 120-126. PMID 33310432 DOI: 10.1016/j.gaitpost.2020.11.025 |
0.087 |
|
| 2023 |
Colloud S, Metcalfe T, Askin S, Belachew S, Ammann J, Bos E, Kilchenmann T, Strijbos P, Eggenspieler D, Servais L, Garay C, Konstantakopoulos A, Ritzhaupt A, Vetter T, Vincenzi C, et al. Evolving regulatory perspectives on digital health technologies for medicinal product development. Npj Digital Medicine. 6: 56. PMID 36991116 DOI: 10.1038/s41746-023-00790-2 |
0.078 |
|
| 2016 |
Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, Belachew S, Hyde R, Verheul F, Lugaresi A, Havrdová E, Horáková D, Grammond P, Duquette P, Prat A, et al. Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS. Neurology. Clinical Practice. 6: 102-115. PMID 27104064 DOI: 10.1212/CPJ.0000000000000227 |
0.078 |
|
| 2022 |
Gafson AR, Jiang X, Shen C, Kapoor R, Zetterberg H, Fox RJ, Belachew S. Serum Neurofilament Light and Multiple Sclerosis Progression Independent of Acute Inflammation. Jama Network Open. 5: e2147588. PMID 35133438 DOI: 10.1001/jamanetworkopen.2021.47588 |
0.077 |
|
| 2022 |
Pang M, Zhu L, Gabelle A, Gafson AR, Platt RW, Galvin JE, Krolak-Salmon P, Rubino I, de Moor C, Belachew S, Shen C. Toward the end of a controversy on the effect of reduction in brain amyloid levels on change in cognitive and functional decline in Alzheimer's disease-Reply to a letter. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 36383475 DOI: 10.1002/alz.12864 |
0.073 |
|
| 2022 |
Graves JS, Ganzetti M, Dondelinger F, Lipsmeier F, Belachew S, Bernasconi C, Montalban X, van Beek J, Baker M, Gossens C, Lindemann M. Preliminary validity of the Draw a Shape Test for upper extremity assessment in multiple sclerosis. Annals of Clinical and Translational Neurology. PMID 36563127 DOI: 10.1002/acn3.51705 |
0.068 |
|
| 2023 |
Pang M, Gabelle A, Saha-Chaudhuri P, Huijbers W, Gafson A, Matthews PM, Tian L, Rubino I, Hughes R, de Moor C, Belachew S, Shen C. Precision medicine analysis of heterogeneity in individual-level treatment response to amyloid beta removal in early Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37882364 DOI: 10.1002/alz.13431 |
0.065 |
|
| 2022 |
Pang M, Zhu L, Gabelle A, Gafson AR, Platt RW, Galvin JE, Krolak-Salmon P, Rubino I, de Moor C, Belachew S, Shen C. Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: An instrumental variable meta-analysis. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 36043526 DOI: 10.1002/alz.12768 |
0.065 |
|
| 2021 |
Montalban X, Graves J, Midaglia L, Mulero P, Julian L, Baker M, Schadrack J, Gossens C, Ganzetti M, Scotland A, Lipsmeier F, van Beek J, Bernasconi C, Belachew S, Lindemann M, et al. A smartphone sensor-based digital outcome assessment of multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 13524585211028561. PMID 34259588 DOI: 10.1177/13524585211028561 |
0.064 |
|
| 2023 |
Elliott C, Rudko DA, Arnold DL, Fetco D, Elkady AM, Araujo D, Zhu B, Gafson A, Tian Z, Belachew S, Bradley DP, Fisher E. Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 13524585231162262. PMID 37036134 DOI: 10.1177/13524585231162262 |
0.062 |
|
| 2024 |
Sima DM, Phan TV, Van Eyndhoven S, Vercruyssen S, Magalhães R, Liseune A, Brys A, Frenyo P, Terzopoulos V, Maes C, Guo J, Hughes R, Gabr RE, Huijbers W, Saha-Chaudhuri P, ... ... Belachew S, et al. Artificial Intelligence Assistive Software Tool for Automated Detection and Quantification of Amyloid-Related Imaging Abnormalities. Jama Network Open. 7: e2355800. PMID 38345816 DOI: 10.1001/jamanetworkopen.2023.55800 |
0.053 |
|
| 2008 |
Cuvelier ML, Léonard P, Rikir E, Belachew S. [When HIV gets into the brain]. Revue Mã©Dicale De Liã¨Ge. 63: 338-41. PMID 18669201 |
0.053 |
|
| 2019 |
Midaglia L, Mulero P, Montalban X, Graves J, Hauser SL, Julian L, Baker M, Schadrack J, Gossens C, Scotland A, Lipsmeier F, van Beek J, Bernasconi C, Belachew S, Lindemann M. Correction: Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study. Journal of Medical Internet Research. 21: e16287. PMID 31596725 DOI: 10.2196/16287 |
0.052 |
|
| 2006 |
Pirard L, Belachew S, Trotteur G, Van Damme H. [Clinical case of the month. Cerebrovascular accident related to arterial brachiocephalic trunk stenosis]. Revue Mã©Dicale De Liã¨Ge. 61: 553-8. PMID 17020227 |
0.052 |
|
| 2022 |
Guo CC, Chiesa PA, de Moor C, Fazeli MS, Schofield T, Hofer K, Belachew S, Scotland A. Digital Devices for Assessing Motor Functions in Mobility-Impaired and Healthy Populations: Systematic Literature Review. Journal of Medical Internet Research. 24: e37683. PMID 36409538 DOI: 10.2196/37683 |
0.03 |
|
| Hide low-probability matches. |